Stockscreener 앱 받기
12.16
1.94%
-0.24
시간 외 거래:
12.13
-0.03
-0.25%
전일 마감가:
$12.40
열려 있는:
$12.3
하루 거래량:
200.88K
Relative Volume:
0.76
시가총액:
$454.62M
수익:
$50.00M
순이익/손실:
$-58.44M
주가수익비율:
-6.2273
EPS:
-1.9527
순현금흐름:
$-57.73M
1주 성능:
+7.61%
1개월 성능:
-11.37%
6개월 성능:
+5.92%
1년 성능:
+209.41%
1일 변동 폭
$11.87
$13.10
1주일 범위
$11.35
$13.32
52주 변동 폭
$3.57
$16.33
Contineum Therapeutics Inc Stock (CTNM) Company Profile
명칭
Contineum Therapeutics Inc
전화
(858) 333-5280
주소
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
12.16 | 475.55M | 50.00M | -58.44M | -57.73M | -1.9527 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-09-25 | 개시 | Leerink Partners | Outperform |
| 2025-06-20 | 개시 | William Blair | Outperform |
| 2024-10-22 | 개시 | Robert W. Baird | Outperform |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-30 | 개시 | Stifel | Buy |
모두보기
Contineum Therapeutics Inc 주식(CTNM)의 최신 뉴스
Number of shareholders of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
CTNM Q1 2026 Earnings: Narrower-than-Expected Loss Surprises MarketsProfit Announcement - newsline.com
CTNM: PIPE-791 advances in IPF with strong differentiation, robust pipeline, and solid financial runway - TradingView
CTNM: PIPE-791 advances in IPF with best-in-class potential, strong safety, and robust clinical momentum - TradingView
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Contineum Therapeutics CSO Daniel Lorrain sells $54,862 in stock - Investing.com
Contineum Therapeutics (CTNM) CSO sells 4,170 shares under 10b5-1 plan - Stock Titan
CTNM insider 10b5-1 sales recorded by Morgan Stanley (CTNM) - Stock Titan
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - Weekly Voice
CTNM Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesEarnings Turnaround - newsline.com
Contineum Therapeutics, Inc.Common stock (CTNM) Stock Price, News, Quote & History - FinancialContent
Contineum Therapeutics (CTNM) Retreats 1.08% – Key Support Level in FocusModified Schiff - The Legal Advocate
Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Narrower Loss Beats ExpectationsEarnings Beat Alert - newsline.com
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - MSN
CTNM Q1 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Maintains DisciplineFinal Results - The Legal Advocate
Contineum Therapeutics (CTNM) Declines 3.55%, Testing Key Support at $13.17Swing Trade Setups - Newser
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Yahoo Finance Singapore
Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower Loss, Shares DipFinancial Data - newsline.com
CTNM Q1 2026 Earnings: Narrower-than-Expected Loss Drives Strong EPS Surprise, but Shares SlipExpert Market Insights - Newser
CTNM Q1 2026 Earnings: Narrowed Loss Exceeds Expectations as Pipeline AdvancesPre-Announcement Alert - newsline.com
CTNM Q1 2026 Earnings: Significant EPS Beat Amid Pipeline Progress, Stock Slightly DownViral Trade Signals - Newser
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential - Yahoo Finance
CTNM Q1 2026 Earnings: EPS Surprise Beats Estimates, Stock Rises Amid R&D ProgressTangible Book Value - The Legal Advocate
Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar - MSN
RA Capital affiliates report 1.296M shares of Contineum (CTNM) - Stock Titan
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
Balyasny Group (CTNM) reports 2.42M shares via ADMF, ~7.40% stake - Stock Titan
Morgan Stanley Raises Price Target on Contineum Therapeutics to $16 From $14, Keeps Equalweight Rating - Moomoo
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $22.33, Implies 58% Upside - TradingView
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference - BioSpace
Stream Contineum’s 2026 RBC Global Healthcare Conference talk live - Stock Titan
Ring Energy Announces Proposed Public Offering of Common Stock - Weekly Voice
TradingKey - TradingKey
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference - BioSpace
Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Capital Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Entrada Therapeutics Inc (TRDA) and Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Contineum Therapeutics Inc (CTNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):